论文部分内容阅读
目的观察贝那普利对慢性心力衰竭(CHF)病人血清抵抗素水平的影响及其临床意义。方法选取CHF组病人62例,正常对照组40例。所有研究对象均测定心脏左室射血分数(LVEF)、血清高敏C反应蛋白(hs-CRP)和抵抗素水平。CHF组又分为对照亚组和治疗亚组,对照亚组给予利尿剂、硝酸酯类药物等常规治疗,治疗亚组除常规治疗外还给予贝那普利片口服6个月(10mg/日),对比两组病人的LVEF、hs-CRP和抵抗素水平。结果与正常对照组对比,CHF组患者的LVEF明显降低(P<0.01),血清hs-CRP、抵抗素均有显著升高(P<0.01)。与CHF对照亚组比较,CHF治疗亚组病人LVEF进一步改善(P<0.05),血清hs-CRP和抵抗素水平明显升高(P<0.01)。结论抵抗素可能在CHF的发病中起着重要的作用,贝那普利可以降低抵抗素水平,增加LVEF,改善心功能。
Objective To observe the effect of benazepril on serum resistin in patients with chronic heart failure (CHF) and its clinical significance. Methods CHF patients were selected 62 cases, 40 cases of normal control group. All subjects were measured cardiac left ventricular ejection fraction (LVEF), serum high-sensitivity C-reactive protein (hs-CRP) and resistin levels. The CHF group was divided into control subgroup and treatment subgroup. The control subgroup was given routine treatment such as diuretic and nitrates. The treatment subgroup was treated with benazepril orally for 6 months (10mg / day) ), LVEF, hs-CRP and resistin levels in two groups were compared. Results Compared with the normal control group, the LVEF in CHF group was significantly lower (P <0.01) and the serum hs-CRP and resistin levels were significantly higher (P <0.01). Compared with the CHF control subgroup, LVEF was further improved in CHF subgroup (P <0.05), serum hs-CRP and resistin levels were significantly increased (P <0.01). Conclusion Resistin may play an important role in the pathogenesis of CHF. Benazepril can reduce the level of resistin, increase LVEF and improve cardiac function.